ObjectiveGI is delivering provider partners and their patients participating in research a new, all-inclusive platform of clinical research data management.
“Our distributed technology further strengthens ObjectiveGI’s relationships with partner physicians by delivering more information and analytics within the framework of their existing patient care workflows,” says Colleen Hoke, CEO. “This ‘frictionless’ information-sharing approach supports mobile engagement for investigators, improving workflow integration and timely access to clinical research data.”
“This collaboration extends our data-driven solutions platform while maintaining our stringent security and data privacy requirements. The Clinical Research IO product infrastructure adheres to a stringent cloud-readiness process with security reviews, penetration testing and redundancy,” says Gerry Andrady, CTO. The new ObjectiveGI platform incorporates a clinical research–based eSource model that accepts multiple data formats and securely transforms those data sets into more comprehensive reporting and analytics. The result is usable information that can be readily reviewed and utilized within trial management.
ObjectiveGI is engaging next generation research systems to leverage resources and accelerate high-quality data collection, thus allowing for more efficient research execution throughout the patient care continuum.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.